Versameb

Versameb AG is a privately held company focusing on discovering and developing innovative RNA-based drugs for indications of unmet medical need.

[Versameb @versameb]

𝗩𝗲𝗿𝘀𝗮𝗺𝗲𝗯 CEO Klaas Zuideveld joins Sabine Hutchison from @SeussPlus on Cut the Chat to talk RNA therapies for stress urinary incontinence—and why women’s health needs more attention and funding. 🎧

📺Full episode on Spotify: https://t.co/pjrJWaStce
#WomensHealth #mRNA

[Versameb @versameb]

🎉Versameb AG secures its first patent in China for signal peptide technology! This milestone advances RNA-based therapeutics, improving protein delivery and expression. Proud of our team's dedication to innovation. See https://t.co/qjhiX3M5lM. #Versameb #mRNA #Innovation #Patent

[Versameb @versameb]

💪Together, let's break barriers in SUI treatment and empower women worldwide. Follow our journey and join the cause this International Women’s Day.

#EmpoweringWomen #BreakingBarriers #SUITreatment #Versameb #InternationalWomensDay #incontinence #RNATherapeutics

[Versameb @versameb]

🌟Join us this International Women’s Day in spotlighting a crucial issue affecting millions of women worldwide: Stress Urinary Incontinence (SUI). At @versameb, we are committed to revolutionizing SUI treatment, empowering women worldwide to reclaim control of their lives.

[Versameb @versameb]

🔬Our dedicated team is advancing an innovative treatment for SUI, aiming to restore physiological bladder function and provide long-term relief. But we can't do it alone – we need your support!

[Versameb @versameb]

@versameb is pleased to announce the publication of data in Molecular Therapy - Nucleic Acids Journal. The manuscript reveals how our innovative approach to #mRNA therapeutics has the potential to transform the landscape of regenerative medicine.
https://t.co/JZE57jK8Hi

[Versameb @versameb]

@versameb is pleased to name Dr. Alexandre LeBeaut as Chair of its Board of Directors.
Dr. LeBeaut has over two decades of global R&D leadership experiences, successfully bringing multiple medicines to market.
Read the full PR, here: https://t.co/WfMket3ZxR
#CompanyGrowth #mRNA

[Touchlight @TouchlightDNA]

PRESS RELEASE 👉 Touchlight’s enzymatic doggybone DNA used in the manufacture of @versameb’s VMB-100 for first-in-human clinical study.

Read the full press release here - https://t.co/LK3nIe6dSZ

[Versameb @versameb]

@versameb is delighted to announce FDA clearance of IND Application for its lead candidate VMB-100 in the treatment of stress urinary incontinence (SUI).
Read more here: https://t.co/Bp1F5rqPqQ
#FDA #IND #urology #SUI #incontinence #mRNA #clinicaldevelopment

[Versameb @versameb]

Congratulations @kkariko and Dr Drew Weissman, who where jointly awarded the @NobelPrize 2023 by The Nobel Assembly for their discoveries concerning nucleoside base modifications that enabled the development of effective #mRNA vaccines against #COVID-19.

[Versameb @versameb]

@versameb's lead candidate VMB-100, a potential treatment for #SUI, is edging closer to #clinicaldevelopment. Read more about its potential to transform women's health outcomes in @DDWJournal: https://t.co/4imfQbcB4y

[Versameb @versameb]

@Uroweb (#EAU) has highlighted the economic burden of #incontinence and the current costs to the European society which are estimated to be over 40 billion Euros each year, with accumulated costs set to rise to EUR 320 billion by 2030. Learn more here: https://t.co/UdelVjPpog

[Versameb @versameb]

Our Chief Medical Officer, Roger Dmochowski, will be attending the @icsoffice (International Continence Society) Annual Meeting in Toronto this week, 27-29 September. Follow @versameb to explore the latest insights and advancements in #incontinence care. See you there!

[Versameb @versameb]

This #UrologyAwarenessMonth, @versameb aims to raise awareness about Stress Urinary Incontinence (#SUI), a very common problem, with a detrimental impact on everyday life for countless women worldwide. Find out more on the @Labiotech_eu podcast: https://t.co/6PyxoLsj2p

[Versameb @versameb]

Our CMO, Professor Roger Dmochowski, is a world-leading KOL in female urology and urologic reconstruction. Roger discusses the potential of mRNA therapeutics in the treatment of #SUI with @DrugTargetRev here: https://t.co/PTVj04GqFF #UAM23

[Versameb @versameb]

#SUI impacts millions worldwide, with no approved drug treatment that restores physiological #bladder function. Listen to the @versameb team speak about their plans to revolutionize SUI therapy on the @OptimumComms podcast: https://t.co/M2Lg1ksfv3 #UAM23

[Versameb @versameb]

September is #UrologyAwarenessMonth supported by @versameb which is committed to finding an effective treatment for Stress Urinary Incontinence (#SUI). Hear CEO, Klaas Zuideveld, discuss the potential of mRNA therapeutics in a recent @DDWJournal webinar: https://t.co/ORiMi486A3

[Versameb @versameb]

Our CEO, Klaas Zuideveld was a featured speaker at the latest @DDWJournal webinar entitled "Where are the breakthroughs in mRNA drug discovery and
Link to webinar here: https://t.co/tzcOE1jQVG
#urology #oncology #SUI #incontinence #mRNA #clinicaldevelopment